CCR2 and neoplasm: Therapeutic strategies targeting TAMs are rapidly evolving and include agents that block macrophage recruitment (e.g., CCR2 or CSF1R inhibitors), reprogram TAMs toward M1-like anti-tumor phenotypes, or deplete pro-tumoral populations [87,88].